Trial · NCT04114539
Outcomes28
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
21 to 28 of 28
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Electrocardiogram (ECG) Values Parameters: Aggregate PR Interval, Aggregate QRS Duration, Aggregate QT Interval, and Aggregate QTc Interval | Baseline to Month 12 | The Safety Set included all participants who received at least one dose of study drug from the open labelled study. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure. | millisecond (msec) | MEAN |
| PRIMARY | Number of Participants With Clinically Significant Abnormal Physical Examination Findings | Baseline up to Month 12 | The Safety Set included all participants who received at least one dose of study drug from the open labelled study. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure and Number Analyzed signifies participants who were evaluable at the specified categories. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Change From Baseline in the Yale Global Tic Severity Scale -Total Tic Score (YGTSS-TTS) at Months 1, 3, 6, 9 and 12 | Baseline up to Months 1, 3, 6, 9 and 12 | The mITT set included all participants who received at least one dose of study drug and had at least one post Baseline scoring of YGTSS. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure and Number Analyzed signifies participants who were evaluable at specified timepoint. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in the Yale Global Tic Severity Scale - Impairment (YGTSS-I) at Months 1, 3, 6, 9 and 12 | Baseline up to Months 1, 3, 6, 9 and 12 | The mITT set included all participants who received at least one dose of study drug and had at least one post Baseline scoring of YGTSS. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure and Number Analyzed signifies participants who were evaluable at specified timepoint. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in the Yale Global Tic Severity Scale - Global Score (YGTSS-GS) at Months 1, 3, 6, 9 and 12 | Baseline up to Months 1, 3, 6, 9 and 12 | The mITT set included all participants who received at least one dose of study drug and had at least one post Baseline scoring of YGTSS. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure and Number Analyzed signifies participants who were evaluable at specified timepoint. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Clinical Global Impression of Tourette Syndrome of Severity (CGI-TS-S) at Months 1, 3, 6, 9, 12 | Baseline up to Months 1, 3, 6, 9, 12 | The mITT set included all participants who received at least one dose of study drug and had at least one post Baseline scoring of YGTSS. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure and Number Analyzed signifies participants who were evaluable at specified timepoint. | score on a scale | MEAN |
| SECONDARY | Clinical Global Impression Tourette Syndrome of Improvement (CGI-TS-I) Scores at Months 1, 3, 6, 9 and 12 | Months 1, 3, 6, 9 and 12 | The mITT set included all participants who received at least one dose of study drug and had at least one post Baseline scoring of YGTSS. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure and Number Analyzed signifies participants who were evaluable at specified timepoint. | score on a scale | MEAN |
| SECONDARY | Change From Baseline in Gilles de la Tourette Syndrome-Quality of Life Scale for Children and Adolescents (C&A-GTS-QOL) Total Score at Months 1, 3, 6, 9 and 12 | Baseline up to Months 1, 3, 6, 9 and 12 | The mITT set included all participants who received at least one dose of study drug and had at least one post Baseline scoring of YGTSS. Here, Overall Number of Participants Analyzed signifies participants who were evaluable for this outcome measure and Number Analyzed signifies participants who were evaluable at specified timepoint. | score on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04114539/outcomes?page=2